We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Oncocyte Corporation | NASDAQ:OCX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.0494 | -1.78% | 2.73 | 2.67 | 2.73 | 2.80 | 2.625 | 2.78 | 13,122 | 18:01:36 |
From May 2021 to May 2024
By Chris Wack
Oncocyte Corp. shares fell 11% to $1.95 after the company said it was in a development and co-marketing agreement for two distributed in vitro diagnostic assays on Thermo Fisher Scientific's Ion Torrent Genexus System.
The company said the agreement grants Oncocyte rights to develop future companion diagnostics on the Genexus System.
Under the terms of the collaboration, Oncocyte will clinically validate Thermo Fisher's existing Oncomine Comprehensive Assay Plus on the Genexus System, working toward IVD clearance for use in tumor profiling and future submissions as a companion diagnostic.
Oncocyte shares ended Tuesday's session up 16%, and hit their 52-week low of $1.80 on Jan. 14.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 19, 2022 10:13 ET (15:13 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Oncocyte Chart |
1 Month Oncocyte Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
